The UPI (8/30) reported that thiazolidinediones, “a class of oral drugs used to treat type 2 diabetes, may increase the risk of heart failure,” according to an editorial published in the journal Heart. In the editorial, physicians from Wake Forest University School of Medicine “strongly recommend restrictions in the use of thiazolidinediones…and question the rationale for leaving rosiglitazone on the market. Rosiglitazone and pioglitazone are the two major thiazolidinediones.” Previously, the authors found that “thiazolidinediones doubled the risk of congestive heart failure in patients with type 2 diabetes,” and this “appears to be a class effect.”
